Wolfe Research analyst Alexandria Hammond reiterated a Peerperform rating and {REMOVEPT} price target on Biogen (NASDAQ: BIIB).The analyst comments "Biogen's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Mizuho Reiterates Outperform Rating on Biogen (BIIB)May 14, 2026 8:17 AM Stifel on Biogen (BIIB): 'We want to be a little cautious here until we see the full data'May 14, 2026 7:29 AM Biogen stock jumps 10% on positive phase 2 diranersen data for Alzheimer’sMay 14, 2026 7:16 AM Biogen's diranersen shows tau reduction in Alzheimer's trialMay 14, 2026 6:59 AM Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s DiseaseMay 14, 2026 6:59 AM